Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot
Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
| Page standards status: Informative |
@prefix fhir: <http://hl7.org/fhir/> . @prefix owl: <http://www.w3.org/2002/07/owl#> . @prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> . @prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> . @prefix xsd: <http://www.w3.org/2001/XMLSchema#> . # - resource ------------------------------------------------------------------- a fhir:Composition ; fhir:nodeRole fhir:treeRoot ; fhir:id [ fhir:v "370504"] ; # fhir:meta [ fhir:versionId [ fhir:v "24" ] ; fhir:lastUpdated [ fhir:v "2025-08-18T13:22:42.074Z"^^xsd:dateTime ] ; ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/outcome-measure-report"^^xsd:anyURI ; fhir:link <http://hl7.org/fhir/uv/ebm/StructureDefinition/outcome-measure-report> ] ) ] ; # fhir:text [ fhir:status [ fhir:v "extensions" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Composition 370504</b></p><a name=\"370504\"> </a><a name=\"hc370504\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">version: 24; Last updated: 2025-08-18 13:22:42+0000</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-outcome-measure-report.html\">OutcomeMeasureReport</a></p></div><p><b>ArtifactPublicationStatus</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-status-type active}\">Active</span></p><p><b>url</b>: <a href=\"https://fevir.net/resources/Composition/370504\">https://fevir.net/resources/Composition/370504</a></p><p><b>identifier</b>: FEvIR Object Identifier/370504, FEvIR Linking Identifier/NCT03640312-outcome-measure-report</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 OutcomeMeasureReport}\">Outcome Measure Report</span></p><p><b>date</b>: 2025-08-18 13:22:42+0000</p><p><b>author</b>: [No author listed.]</p><p><b>title</b>: Outcome Measures Report for NCT03640312</p><p><b>custodian</b>: <a href=\"Organization-118079.html\">Computable Publishing LLC</a></p><h3>RelatesTos</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Target[x]</b></td></tr><tr><td style=\"display: none\">*</td><td>Cite As</td><td><div><p>Outcome Measures Report for NCT03640312 [Database Entry: FHIR Composition Resource]. Contributors: [No author listed.] [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 370504. Revised 2025-08-18. Available at: https://fevir.net/resources/Composition/370504. Computable resource at: https://fevir.net/FLI/DocumentForComposition370504.</p>\n</div></td></tr></table></div>"^^rdf:XMLLiteral ] ; # fhir:extension ( [ fhir:url [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status"^^xsd:anyURI ] ; fhir:value [ a fhir:CodeableConcept ; ( fhir:coding [ fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "active" ] ; fhir:display [ fhir:v "Active" ] ] ) ] ] ) ; # fhir:url [ fhir:v "https://fevir.net/resources/Composition/370504"^^xsd:anyURI] ; # fhir:identifier ( [ fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/v2-0203"^^xsd:anyURI ] ; fhir:code [ fhir:v "ACSN" ] ; fhir:display [ fhir:v "Accession ID" ] ] ) ; fhir:text [ fhir:v "FEvIR Object Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FOI"^^xsd:anyURI ] ; fhir:value [ fhir:v "370504" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-outcome-measure-report" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ) ; # fhir:status [ fhir:v "final"] ; # fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ] ; fhir:code [ fhir:v "OutcomeMeasureReport" ] ; fhir:display [ fhir:v "OutcomeMeasureReport" ] ] ) ; fhir:text [ fhir:v "Outcome Measure Report" ] ] ; # fhir:date [ fhir:v "2025-08-18T13:22:42.074Z"^^xsd:dateTime] ; # fhir:author ( [ fhir:display [ fhir:v "[No author listed.]" ] ] ) ; # fhir:title [ fhir:v "Outcome Measures Report for NCT03640312"] ; # fhir:custodian [ fhir:reference [ fhir:v "Organization/118079" ] ; fhir:type [ fhir:v "Organization"^^xsd:anyURI ] ; fhir:display [ fhir:v "Computable Publishing LLC" ] ] ; # fhir:relatesTo ( [ fhir:type [ fhir:v "cite-as" ] ; fhir:target [ a fhir:markdown ; fhir:v "Outcome Measures Report for NCT03640312 [Database Entry: FHIR Composition Resource]. Contributors: [No author listed.] [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 370504. Revised 2025-08-18. Available at: https://fevir.net/resources/Composition/370504. Computable resource at: https://fevir.net/FLI/DocumentForComposition370504." ] ] ) ; # fhir:section ( [ fhir:title [ fhir:v "Change in Mean Systolic Blood Pressure at 12 weeks" ] ; fhir:focus [ fhir:reference [ fhir:v "EvidenceVariable/367882" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-primaryOutcome-0" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Change in Mean Systolic Blood Pressure at 12 weeks (NCT03640312)" ] ] ; ( fhir:section [ fhir:title [ fhir:v "Outcome Measure Population Description" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasurePopulationDescription" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Measure Reporting Status" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasureReportingStatus" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Measure Time Frame" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasureTimeFrame" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Group List" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeGroupList" ] ] ; ( fhir:section [ fhir:title [ fhir:v "QUARTET LDQT" ] ; fhir:code [ fhir:text [ fhir:v "OG000" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"^^rdf:XMLLiteral ] ; ( fhir:entry [ fhir:display [ fhir:v "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks." ] ] ) ] [ fhir:title [ fhir:v "Candesartan" ] ; fhir:code [ fhir:text [ fhir:v "OG001" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"^^rdf:XMLLiteral ] ; ( fhir:entry [ fhir:display [ fhir:v "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks." ] ] ) ] ) ] [ fhir:title [ fhir:v "Outcome Class List" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeClassList" ] ] ; ( fhir:section [ fhir:title [ fhir:v "Change in Mean Systolic Blood Pressure at 12 weeks (NCT03640312)" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:reference [ fhir:v "EvidenceVariable/367882" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-primaryOutcome-0" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Change in Mean Systolic Blood Pressure at 12 weeks (NCT03640312)" ] ] ; ( fhir:entry [ fhir:reference [ fhir:v "Evidence/367903" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-primaryOutcomeMeasure-0--OG000" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Change in Mean Systolic Blood Pressure at 12 weeks for QUARTET LDQT in NCT03640312" ] ] [ fhir:reference [ fhir:v "Evidence/367904" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-primaryOutcomeMeasure-0--OG001" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Change in Mean Systolic Blood Pressure at 12 weeks for Candesartan in NCT03640312" ] ] [ fhir:reference [ fhir:v "Evidence/367941" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-primaryOutcomeMeasure-0-OutcomeAnalysis-0-BetweenGroupAnalysis-OG000-OG001" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Change in Mean Systolic Blood Pressure at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312" ] ] ) ] ) ] ) ] [ fhir:title [ fhir:v "Mean Systolic Blood Pressure at 6 weeks" ] ; fhir:focus [ fhir:reference [ fhir:v "EvidenceVariable/367883" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcome-0" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Mean Systolic Blood Pressure at 6 weeks (NCT03640312)" ] ] ; ( fhir:section [ fhir:title [ fhir:v "Outcome Measure Population Description" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasurePopulationDescription" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Measure Reporting Status" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasureReportingStatus" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Measure Time Frame" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasureTimeFrame" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">6 weeks</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Group List" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeGroupList" ] ] ; ( fhir:section [ fhir:title [ fhir:v "QUARTET LDQT" ] ; fhir:code [ fhir:text [ fhir:v "OG000" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"^^rdf:XMLLiteral ] ; ( fhir:entry [ fhir:display [ fhir:v "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks." ] ] ) ] [ fhir:title [ fhir:v "Candesartan" ] ; fhir:code [ fhir:text [ fhir:v "OG001" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"^^rdf:XMLLiteral ] ; ( fhir:entry [ fhir:display [ fhir:v "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks." ] ] ) ] ) ] [ fhir:title [ fhir:v "Outcome Class List" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeClassList" ] ] ; ( fhir:section [ fhir:title [ fhir:v "Mean Systolic Blood Pressure at 6 weeks (NCT03640312)" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:reference [ fhir:v "EvidenceVariable/367883" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcome-0" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Mean Systolic Blood Pressure at 6 weeks (NCT03640312)" ] ] ; ( fhir:entry [ fhir:reference [ fhir:v "Evidence/367905" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcomeMeasure-0--OG000" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312" ] ] [ fhir:reference [ fhir:v "Evidence/367906" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcomeMeasure-0--OG001" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312" ] ] [ fhir:reference [ fhir:v "Evidence/367942" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcomeMeasure-0-OutcomeAnalysis-1-BetweenGroupAnalysis-OG000-OG001" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312" ] ] ) ] ) ] ) ] [ fhir:title [ fhir:v "Change in Mean Diastolic Blood Pressure at 6 weeks" ] ; fhir:focus [ fhir:reference [ fhir:v "EvidenceVariable/367884" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcome-1" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Change in Mean Diastolic Blood Pressure at 6 weeks (NCT03640312)" ] ] ; ( fhir:section [ fhir:title [ fhir:v "Outcome Measure Population Description" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasurePopulationDescription" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Measure Reporting Status" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasureReportingStatus" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Measure Time Frame" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasureTimeFrame" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">6 weeks</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Group List" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeGroupList" ] ] ; ( fhir:section [ fhir:title [ fhir:v "QUARTET LDQT" ] ; fhir:code [ fhir:text [ fhir:v "OG000" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"^^rdf:XMLLiteral ] ; ( fhir:entry [ fhir:display [ fhir:v "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks." ] ] ) ] [ fhir:title [ fhir:v "Candesartan" ] ; fhir:code [ fhir:text [ fhir:v "OG001" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"^^rdf:XMLLiteral ] ; ( fhir:entry [ fhir:display [ fhir:v "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks." ] ] ) ] ) ] [ fhir:title [ fhir:v "Outcome Class List" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeClassList" ] ] ; ( fhir:section [ fhir:title [ fhir:v "Change in Mean Diastolic Blood Pressure at 6 weeks (NCT03640312)" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:reference [ fhir:v "EvidenceVariable/367884" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcome-1" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Change in Mean Diastolic Blood Pressure at 6 weeks (NCT03640312)" ] ] ; ( fhir:entry [ fhir:reference [ fhir:v "Evidence/367907" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcomeMeasure-1--OG000" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Change in Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312" ] ] [ fhir:reference [ fhir:v "Evidence/367908" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcomeMeasure-1--OG001" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Change in Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312" ] ] [ fhir:reference [ fhir:v "Evidence/367943" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcomeMeasure-1-OutcomeAnalysis-2-BetweenGroupAnalysis-OG000-OG001" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Change in Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312" ] ] ) ] ) ] ) ] [ fhir:title [ fhir:v "Mean Diastolic Blood Pressure at 6 weeks" ] ; fhir:focus [ fhir:reference [ fhir:v "EvidenceVariable/367885" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcome-2" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Mean Diastolic Blood Pressure at 6 weeks (NCT03640312)" ] ] ; ( fhir:section [ fhir:title [ fhir:v "Outcome Measure Population Description" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasurePopulationDescription" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Measure Reporting Status" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasureReportingStatus" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Measure Time Frame" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasureTimeFrame" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">6 weeks</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Group List" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeGroupList" ] ] ; ( fhir:section [ fhir:title [ fhir:v "QUARTET LDQT" ] ; fhir:code [ fhir:text [ fhir:v "OG000" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"^^rdf:XMLLiteral ] ; ( fhir:entry [ fhir:display [ fhir:v "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks." ] ] ) ] [ fhir:title [ fhir:v "Candesartan" ] ; fhir:code [ fhir:text [ fhir:v "OG001" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"^^rdf:XMLLiteral ] ; ( fhir:entry [ fhir:display [ fhir:v "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks." ] ] ) ] ) ] [ fhir:title [ fhir:v "Outcome Class List" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeClassList" ] ] ; ( fhir:section [ fhir:title [ fhir:v "Mean Diastolic Blood Pressure at 6 weeks (NCT03640312)" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:reference [ fhir:v "EvidenceVariable/367885" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcome-2" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Mean Diastolic Blood Pressure at 6 weeks (NCT03640312)" ] ] ; ( fhir:entry [ fhir:reference [ fhir:v "Evidence/367909" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcomeMeasure-2--OG000" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312" ] ] [ fhir:reference [ fhir:v "Evidence/367910" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcomeMeasure-2--OG001" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312" ] ] [ fhir:reference [ fhir:v "Evidence/367944" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcomeMeasure-2-OutcomeAnalysis-3-BetweenGroupAnalysis-OG000-OG001" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312" ] ] ) ] ) ] ) ] [ fhir:title [ fhir:v "Proportion of Patients With Hypertension Control at 6 and 12 weeks" ] ; fhir:focus [ fhir:reference [ fhir:v "EvidenceVariable/367886" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcome-3" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Proportion of Patients With Hypertension Control at 6 and 12 weeks (NCT03640312)" ] ] ; ( fhir:section [ fhir:title [ fhir:v "Outcome Measure Population Description" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasurePopulationDescription" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Measure Reporting Status" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasureReportingStatus" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Measure Time Frame" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasureTimeFrame" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">6 and 12 weeks</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Group List" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeGroupList" ] ] ; ( fhir:section [ fhir:title [ fhir:v "QUARTET LDQT" ] ; fhir:code [ fhir:text [ fhir:v "OG000" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"^^rdf:XMLLiteral ] ; ( fhir:entry [ fhir:display [ fhir:v "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks." ] ] ) ] [ fhir:title [ fhir:v "Candesartan" ] ; fhir:code [ fhir:text [ fhir:v "OG001" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"^^rdf:XMLLiteral ] ; ( fhir:entry [ fhir:display [ fhir:v "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks." ] ] ) ] ) ] [ fhir:title [ fhir:v "Outcome Class List" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeClassList" ] ] ; ( fhir:section [ fhir:title [ fhir:v "Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks at (NCT03640312)" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:reference [ fhir:v "EvidenceVariable/370506" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcome-3-6-weeks-" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks at (NCT03640312)" ] ] ; ( fhir:entry [ fhir:reference [ fhir:v "Evidence/367911" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcomeMeasure-3-6-weeks-OG000" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for QUARTET LDQT in NCT03640312" ] ] [ fhir:reference [ fhir:v "Evidence/367912" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcomeMeasure-3-6-weeks-OG001" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for Candesartan in NCT03640312" ] ] ) ] [ fhir:title [ fhir:v "Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks at (NCT03640312)" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:reference [ fhir:v "EvidenceVariable/370507" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcome-3-12-weeks-" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks at (NCT03640312)" ] ] ; ( fhir:entry [ fhir:reference [ fhir:v "Evidence/367913" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcomeMeasure-3-12-weeks-OG000" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for QUARTET LDQT in NCT03640312" ] ] [ fhir:reference [ fhir:v "Evidence/367914" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcomeMeasure-3-12-weeks-OG001" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for Candesartan in NCT03640312" ] ] ) ] ) ] [ fhir:title [ fhir:v "Outcome Analysis List for Proportion of Patients With Hypertension Control at 6 and 12 weeks (NCT03640312)" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ; fhir:text [ fhir:v "OutcomeAnalysisList" ] ] ; fhir:focus [ fhir:reference [ fhir:v "EvidenceVariable/367886" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcome-3" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Proportion of Patients With Hypertension Control at 6 and 12 weeks (NCT03640312)" ] ] ; ( fhir:entry [ fhir:reference [ fhir:v "Evidence/367945" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcomeMeasure-3-OutcomeAnalysis-4-BetweenGroupAnalysis-OG000-OG001" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Proportion of Patients With Hypertension Control at 6 and 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312" ] ] ) ] ) ] [ fhir:title [ fhir:v "Number of Patients Requiring Step up Treatment at 6 weeks" ] ; fhir:focus [ fhir:reference [ fhir:v "EvidenceVariable/367887" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcome-4" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Number of Patients Requiring Step up Treatment at 6 weeks (NCT03640312)" ] ] ; ( fhir:section [ fhir:title [ fhir:v "Outcome Measure Population Description" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasurePopulationDescription" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Measure Reporting Status" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasureReportingStatus" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Measure Time Frame" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasureTimeFrame" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">6 weeks</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Group List" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeGroupList" ] ] ; ( fhir:section [ fhir:title [ fhir:v "QUARTET LDQT" ] ; fhir:code [ fhir:text [ fhir:v "OG000" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"^^rdf:XMLLiteral ] ; ( fhir:entry [ fhir:display [ fhir:v "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks." ] ] ) ] [ fhir:title [ fhir:v "Candesartan" ] ; fhir:code [ fhir:text [ fhir:v "OG001" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"^^rdf:XMLLiteral ] ; ( fhir:entry [ fhir:display [ fhir:v "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks." ] ] ) ] ) ] [ fhir:title [ fhir:v "Outcome Class List" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeClassList" ] ] ; ( fhir:section [ fhir:title [ fhir:v "Number of Patients Requiring Step up Treatment at 6 weeks (NCT03640312)" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:reference [ fhir:v "EvidenceVariable/367887" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcome-4" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Number of Patients Requiring Step up Treatment at 6 weeks (NCT03640312)" ] ] ; ( fhir:entry [ fhir:reference [ fhir:v "Evidence/367915" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcomeMeasure-4--OG000" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Number of Patients Requiring Step up Treatment at 6 weeks for QUARTET LDQT in NCT03640312" ] ] [ fhir:reference [ fhir:v "Evidence/367916" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcomeMeasure-4--OG001" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Number of Patients Requiring Step up Treatment at 6 weeks for Candesartan in NCT03640312" ] ] [ fhir:reference [ fhir:v "Evidence/367946" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcomeMeasure-4-OutcomeAnalysis-5-BetweenGroupAnalysis-OG000-OG001" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Number of Patients Requiring Step up Treatment at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312" ] ] ) ] ) ] ) ] [ fhir:title [ fhir:v "Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks" ] ; fhir:focus [ fhir:reference [ fhir:v "EvidenceVariable/367888" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcome-5" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks (NCT03640312)" ] ] ; ( fhir:section [ fhir:title [ fhir:v "Outcome Measure Population Description" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasurePopulationDescription" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Measure Reporting Status" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasureReportingStatus" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Measure Time Frame" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasureTimeFrame" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Group List" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeGroupList" ] ] ; ( fhir:section [ fhir:title [ fhir:v "QUARTET LDQT" ] ; fhir:code [ fhir:text [ fhir:v "OG000" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"^^rdf:XMLLiteral ] ; ( fhir:entry [ fhir:display [ fhir:v "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks." ] ] ) ] [ fhir:title [ fhir:v "Candesartan" ] ; fhir:code [ fhir:text [ fhir:v "OG001" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"^^rdf:XMLLiteral ] ; ( fhir:entry [ fhir:display [ fhir:v "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks." ] ] ) ] ) ] [ fhir:title [ fhir:v "Outcome Class List" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeClassList" ] ] ; ( fhir:section [ fhir:title [ fhir:v "Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks (NCT03640312)" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:reference [ fhir:v "EvidenceVariable/367888" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcome-5" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks (NCT03640312)" ] ] ; ( fhir:entry [ fhir:reference [ fhir:v "Evidence/367917" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcomeMeasure-5--OG000" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for QUARTET LDQT in NCT03640312" ] ] [ fhir:reference [ fhir:v "Evidence/367918" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcomeMeasure-5--OG001" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for Candesartan in NCT03640312" ] ] [ fhir:reference [ fhir:v "Evidence/367947" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcomeMeasure-5-OutcomeAnalysis-6-BetweenGroupAnalysis-OG000-OG001" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312" ] ] ) ] ) ] ) ] [ fhir:title [ fhir:v "Medication Adherence at 12 weeks" ] ; fhir:focus [ fhir:reference [ fhir:v "EvidenceVariable/367889" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcome-6" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Medication Adherence at 12 weeks (NCT03640312)" ] ] ; ( fhir:section [ fhir:title [ fhir:v "Outcome Measure Population Description" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasurePopulationDescription" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Measure Reporting Status" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasureReportingStatus" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Measure Time Frame" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasureTimeFrame" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Group List" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeGroupList" ] ] ; ( fhir:section [ fhir:title [ fhir:v "QUARTET LDQT" ] ; fhir:code [ fhir:text [ fhir:v "OG000" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"^^rdf:XMLLiteral ] ; ( fhir:entry [ fhir:display [ fhir:v "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks." ] ] ) ] [ fhir:title [ fhir:v "Candesartan" ] ; fhir:code [ fhir:text [ fhir:v "OG001" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"^^rdf:XMLLiteral ] ; ( fhir:entry [ fhir:display [ fhir:v "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks." ] ] ) ] ) ] [ fhir:title [ fhir:v "Outcome Class List" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeClassList" ] ] ; ( fhir:section [ fhir:title [ fhir:v "Medication Adherence at 12 weeks (NCT03640312)" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:reference [ fhir:v "EvidenceVariable/367889" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcome-6" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Medication Adherence at 12 weeks (NCT03640312)" ] ] ; ( fhir:entry [ fhir:reference [ fhir:v "Evidence/367919" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcomeMeasure-6--OG000" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Medication Adherence at 12 weeks for QUARTET LDQT in NCT03640312" ] ] [ fhir:reference [ fhir:v "Evidence/367920" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcomeMeasure-6--OG001" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Medication Adherence at 12 weeks for Candesartan in NCT03640312" ] ] [ fhir:reference [ fhir:v "Evidence/367948" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcomeMeasure-6-OutcomeAnalysis-7-BetweenGroupAnalysis-OG000-OG001" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Medication Adherence at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312" ] ] ) ] ) ] ) ] [ fhir:title [ fhir:v "Health-related Quality of Life at 12 weeks" ] ; fhir:focus [ fhir:reference [ fhir:v "EvidenceVariable/367890" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcome-7" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Health-related Quality of Life at 12 weeks (NCT03640312)" ] ] ; ( fhir:section [ fhir:title [ fhir:v "Outcome Measure Population Description" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasurePopulationDescription" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Data are available on only 28 participants in the intervention group for the mental health T score.</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Measure Reporting Status" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasureReportingStatus" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Measure Time Frame" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasureTimeFrame" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Group List" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeGroupList" ] ] ; ( fhir:section [ fhir:title [ fhir:v "QUARTET LDQT" ] ; fhir:code [ fhir:text [ fhir:v "OG000" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"^^rdf:XMLLiteral ] ; ( fhir:entry [ fhir:display [ fhir:v "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks." ] ] ) ] [ fhir:title [ fhir:v "Candesartan" ] ; fhir:code [ fhir:text [ fhir:v "OG001" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"^^rdf:XMLLiteral ] ; ( fhir:entry [ fhir:display [ fhir:v "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks." ] ] ) ] ) ] [ fhir:title [ fhir:v "Outcome Class List" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeClassList" ] ] ; ( fhir:section [ fhir:title [ fhir:v "Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) at (NCT03640312)" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:reference [ fhir:v "EvidenceVariable/370508" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcome-7-Change-in-Physical-Health-T-score--OPEN---PROMIS---CLOSE--" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) at (NCT03640312)" ] ] ; ( fhir:entry [ fhir:reference [ fhir:v "Evidence/367921" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcomeMeasure-7-Change-in-Physical-Health-T-score--OPEN---PROMIS---CLOSE--OG000" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for QUARTET LDQT in NCT03640312" ] ] [ fhir:reference [ fhir:v "Evidence/367922" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcomeMeasure-7-Change-in-Physical-Health-T-score--OPEN---PROMIS---CLOSE--OG001" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for Candesartan in NCT03640312" ] ] ) ] [ fhir:title [ fhir:v "Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) at (NCT03640312)" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:reference [ fhir:v "EvidenceVariable/370509" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcome-7-Change-in-Mental-Health-T-score--OPEN---PROMIS---CLOSE--" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) at (NCT03640312)" ] ] ; ( fhir:entry [ fhir:reference [ fhir:v "Evidence/367923" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcomeMeasure-7-Change-in-Mental-Health-T-score--OPEN---PROMIS---CLOSE--OG000" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for QUARTET LDQT in NCT03640312" ] ] [ fhir:reference [ fhir:v "Evidence/367924" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcomeMeasure-7-Change-in-Mental-Health-T-score--OPEN---PROMIS---CLOSE--OG001" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for Candesartan in NCT03640312" ] ] ) ] ) ] [ fhir:title [ fhir:v "Outcome Analysis List for Health-related Quality of Life at 12 weeks (NCT03640312)" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ; fhir:text [ fhir:v "OutcomeAnalysisList" ] ] ; fhir:focus [ fhir:reference [ fhir:v "EvidenceVariable/367890" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcome-7" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Health-related Quality of Life at 12 weeks (NCT03640312)" ] ] ; ( fhir:entry [ fhir:reference [ fhir:v "Evidence/367949" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcomeMeasure-7-OutcomeAnalysis-8-BetweenGroupAnalysis-OG000-OG001" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312" ] ] [ fhir:reference [ fhir:v "Evidence/367950" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcomeMeasure-7-OutcomeAnalysis-9-BetweenGroupAnalysis-OG000-OG001" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312" ] ] ) ] ) ] [ fhir:title [ fhir:v "Change in Mean Systolic Blood Pressure at 6 weeks" ] ; fhir:focus [ fhir:reference [ fhir:v "EvidenceVariable/367891" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcome-8" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Change in Mean Systolic Blood Pressure at 6 weeks (NCT03640312)" ] ] ; ( fhir:section [ fhir:title [ fhir:v "Outcome Measure Population Description" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasurePopulationDescription" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Measure Reporting Status" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasureReportingStatus" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Measure Time Frame" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasureTimeFrame" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">6 weeks</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Group List" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeGroupList" ] ] ; ( fhir:section [ fhir:title [ fhir:v "QUARTET LDQT" ] ; fhir:code [ fhir:text [ fhir:v "OG000" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"^^rdf:XMLLiteral ] ; ( fhir:entry [ fhir:display [ fhir:v "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks." ] ] ) ] [ fhir:title [ fhir:v "Candesartan" ] ; fhir:code [ fhir:text [ fhir:v "OG001" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"^^rdf:XMLLiteral ] ; ( fhir:entry [ fhir:display [ fhir:v "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks." ] ] ) ] ) ] [ fhir:title [ fhir:v "Outcome Class List" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeClassList" ] ] ; ( fhir:section [ fhir:title [ fhir:v "Change in Mean Systolic Blood Pressure at 6 weeks (NCT03640312)" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:reference [ fhir:v "EvidenceVariable/367891" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcome-8" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Change in Mean Systolic Blood Pressure at 6 weeks (NCT03640312)" ] ] ; ( fhir:entry [ fhir:reference [ fhir:v "Evidence/367925" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcomeMeasure-8--OG000" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Change in Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312" ] ] [ fhir:reference [ fhir:v "Evidence/367926" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcomeMeasure-8--OG001" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Change in Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312" ] ] [ fhir:reference [ fhir:v "Evidence/367951" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-secondaryOutcomeMeasure-8-OutcomeAnalysis-10-BetweenGroupAnalysis-OG000-OG001" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Change in Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312" ] ] ) ] ) ] ) ] [ fhir:title [ fhir:v "Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks" ] ; fhir:focus [ fhir:reference [ fhir:v "EvidenceVariable/367896" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-otherOutcome-0" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks (NCT03640312)" ] ] ; ( fhir:section [ fhir:title [ fhir:v "Outcome Measure Population Description" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasurePopulationDescription" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized participants</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Measure Reporting Status" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasureReportingStatus" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Measure Time Frame" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasureTimeFrame" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Group List" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeGroupList" ] ] ; ( fhir:section [ fhir:title [ fhir:v "QUARTET LDQT" ] ; fhir:code [ fhir:text [ fhir:v "OG000" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"^^rdf:XMLLiteral ] ; ( fhir:entry [ fhir:display [ fhir:v "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks." ] ] ) ] [ fhir:title [ fhir:v "Candesartan" ] ; fhir:code [ fhir:text [ fhir:v "OG001" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"^^rdf:XMLLiteral ] ; ( fhir:entry [ fhir:display [ fhir:v "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks." ] ] ) ] ) ] [ fhir:title [ fhir:v "Outcome Class List" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeClassList" ] ] ; ( fhir:section [ fhir:title [ fhir:v "Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks (NCT03640312)" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:reference [ fhir:v "EvidenceVariable/367896" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-otherOutcome-0" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks (NCT03640312)" ] ] ; ( fhir:entry [ fhir:reference [ fhir:v "Evidence/367927" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-otherOutcomeMeasure-0--OG000" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for QUARTET LDQT in NCT03640312" ] ] [ fhir:reference [ fhir:v "Evidence/367928" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-otherOutcomeMeasure-0--OG001" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for Candesartan in NCT03640312" ] ] [ fhir:reference [ fhir:v "Evidence/367952" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-otherOutcomeMeasure-0-OutcomeAnalysis-11-BetweenGroupAnalysis-OG000-OG001" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312" ] ] ) ] ) ] ) ] [ fhir:title [ fhir:v "Percentage of Participants With Potentially Related Adverse Events at 12 weeks" ] ; fhir:focus [ fhir:reference [ fhir:v "EvidenceVariable/367897" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-otherOutcome-1" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Percentage of Participants With Potentially Related Adverse Events at 12 weeks (NCT03640312)" ] ] ; ( fhir:section [ fhir:title [ fhir:v "Outcome Measure Population Description" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasurePopulationDescription" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized participants</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Measure Reporting Status" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasureReportingStatus" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Measure Time Frame" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasureTimeFrame" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Group List" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeGroupList" ] ] ; ( fhir:section [ fhir:title [ fhir:v "QUARTET LDQT" ] ; fhir:code [ fhir:text [ fhir:v "OG000" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"^^rdf:XMLLiteral ] ; ( fhir:entry [ fhir:display [ fhir:v "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks." ] ] ) ] [ fhir:title [ fhir:v "Candesartan" ] ; fhir:code [ fhir:text [ fhir:v "OG001" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"^^rdf:XMLLiteral ] ; ( fhir:entry [ fhir:display [ fhir:v "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks." ] ] ) ] ) ] [ fhir:title [ fhir:v "Outcome Class List" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeClassList" ] ] ; ( fhir:section [ fhir:title [ fhir:v "Percentage of Participants With Potentially Related Adverse Events at 12 weeks (NCT03640312)" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:reference [ fhir:v "EvidenceVariable/367897" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-otherOutcome-1" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Percentage of Participants With Potentially Related Adverse Events at 12 weeks (NCT03640312)" ] ] ; ( fhir:entry [ fhir:reference [ fhir:v "Evidence/367929" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-otherOutcomeMeasure-1--OG000" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Percentage of Participants With Potentially Related Adverse Events at 12 weeks for QUARTET LDQT in NCT03640312" ] ] [ fhir:reference [ fhir:v "Evidence/367930" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-otherOutcomeMeasure-1--OG001" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Percentage of Participants With Potentially Related Adverse Events at 12 weeks for Candesartan in NCT03640312" ] ] [ fhir:reference [ fhir:v "Evidence/367953" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-otherOutcomeMeasure-1-OutcomeAnalysis-12-BetweenGroupAnalysis-OG000-OG001" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Percentage of Participants With Potentially Related Adverse Events at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312" ] ] ) ] ) ] ) ] [ fhir:title [ fhir:v "Rate of Adverse Events of Special Interest at 12 weeks" ] ; fhir:focus [ fhir:reference [ fhir:v "EvidenceVariable/367898" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-otherOutcome-2" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Rate of Adverse Events of Special Interest at 12 weeks (NCT03640312)" ] ] ; ( fhir:section [ fhir:title [ fhir:v "Outcome Measure Reporting Status" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasureReportingStatus" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Measure Time Frame" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasureTimeFrame" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Group List" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeGroupList" ] ] ; ( fhir:section [ fhir:title [ fhir:v "QUARTET LDQT" ] ; fhir:code [ fhir:text [ fhir:v "OG000" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"^^rdf:XMLLiteral ] ; ( fhir:entry [ fhir:display [ fhir:v "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks." ] ] ) ] [ fhir:title [ fhir:v "Candesartan" ] ; fhir:code [ fhir:text [ fhir:v "OG001" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"^^rdf:XMLLiteral ] ; ( fhir:entry [ fhir:display [ fhir:v "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks." ] ] ) ] ) ] [ fhir:title [ fhir:v "Outcome Class List" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeClassList" ] ] ; ( fhir:section [ fhir:title [ fhir:v "Rate of Adverse Events of Special Interest at 12 weeks (NCT03640312)" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:reference [ fhir:v "EvidenceVariable/367898" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-otherOutcome-2" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Rate of Adverse Events of Special Interest at 12 weeks (NCT03640312)" ] ] ; ( fhir:entry [ fhir:reference [ fhir:v "Evidence/367931" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-otherOutcomeMeasure-2--OG000" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Rate of Adverse Events of Special Interest at 12 weeks for QUARTET LDQT in NCT03640312" ] ] [ fhir:reference [ fhir:v "Evidence/367932" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-otherOutcomeMeasure-2--OG001" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Rate of Adverse Events of Special Interest at 12 weeks for Candesartan in NCT03640312" ] ] [ fhir:reference [ fhir:v "Evidence/367954" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-otherOutcomeMeasure-2-OutcomeAnalysis-13-BetweenGroupAnalysis-OG000-OG001" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Rate of Adverse Events of Special Interest at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312" ] ] ) ] ) ] ) ] [ fhir:title [ fhir:v "Mean Change in Serum Potassium at 12 weeks" ] ; fhir:focus [ fhir:reference [ fhir:v "EvidenceVariable/367899" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-otherOutcome-3" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Mean Change in Serum Potassium at 12 weeks (NCT03640312)" ] ] ; ( fhir:section [ fhir:title [ fhir:v "Outcome Measure Population Description" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasurePopulationDescription" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Measure Reporting Status" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasureReportingStatus" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Measure Time Frame" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasureTimeFrame" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Group List" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeGroupList" ] ] ; ( fhir:section [ fhir:title [ fhir:v "QUARTET LDQT" ] ; fhir:code [ fhir:text [ fhir:v "OG000" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"^^rdf:XMLLiteral ] ; ( fhir:entry [ fhir:display [ fhir:v "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks." ] ] ) ] [ fhir:title [ fhir:v "Candesartan" ] ; fhir:code [ fhir:text [ fhir:v "OG001" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"^^rdf:XMLLiteral ] ; ( fhir:entry [ fhir:display [ fhir:v "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks." ] ] ) ] ) ] [ fhir:title [ fhir:v "Outcome Class List" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeClassList" ] ] ; ( fhir:section [ fhir:title [ fhir:v "Mean Change in Serum Potassium at 12 weeks (NCT03640312)" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:reference [ fhir:v "EvidenceVariable/367899" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-otherOutcome-3" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Mean Change in Serum Potassium at 12 weeks (NCT03640312)" ] ] ; ( fhir:entry [ fhir:reference [ fhir:v "Evidence/367933" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-otherOutcomeMeasure-3--OG000" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Mean Change in Serum Potassium at 12 weeks for QUARTET LDQT in NCT03640312" ] ] [ fhir:reference [ fhir:v "Evidence/367934" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-otherOutcomeMeasure-3--OG001" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Mean Change in Serum Potassium at 12 weeks for Candesartan in NCT03640312" ] ] [ fhir:reference [ fhir:v "Evidence/367955" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-otherOutcomeMeasure-3-OutcomeAnalysis-14-BetweenGroupAnalysis-OG000-OG001" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Mean Change in Serum Potassium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312" ] ] ) ] ) ] ) ] [ fhir:title [ fhir:v "Mean Change in Serum Sodium at 12 weeks" ] ; fhir:focus [ fhir:reference [ fhir:v "EvidenceVariable/367900" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-otherOutcome-4" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Mean Change in Serum Sodium at 12 weeks (NCT03640312)" ] ] ; ( fhir:section [ fhir:title [ fhir:v "Outcome Measure Population Description" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasurePopulationDescription" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Measure Reporting Status" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasureReportingStatus" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Measure Time Frame" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasureTimeFrame" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Group List" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeGroupList" ] ] ; ( fhir:section [ fhir:title [ fhir:v "QUARTET LDQT" ] ; fhir:code [ fhir:text [ fhir:v "OG000" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"^^rdf:XMLLiteral ] ; ( fhir:entry [ fhir:display [ fhir:v "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks." ] ] ) ] [ fhir:title [ fhir:v "Candesartan" ] ; fhir:code [ fhir:text [ fhir:v "OG001" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"^^rdf:XMLLiteral ] ; ( fhir:entry [ fhir:display [ fhir:v "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks." ] ] ) ] ) ] [ fhir:title [ fhir:v "Outcome Class List" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeClassList" ] ] ; ( fhir:section [ fhir:title [ fhir:v "Mean Change in Serum Sodium at 12 weeks (NCT03640312)" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:reference [ fhir:v "EvidenceVariable/367900" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-otherOutcome-4" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Mean Change in Serum Sodium at 12 weeks (NCT03640312)" ] ] ; ( fhir:entry [ fhir:reference [ fhir:v "Evidence/367935" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-otherOutcomeMeasure-4--OG000" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Mean Change in Serum Sodium at 12 weeks for QUARTET LDQT in NCT03640312" ] ] [ fhir:reference [ fhir:v "Evidence/367936" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-otherOutcomeMeasure-4--OG001" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Mean Change in Serum Sodium at 12 weeks for Candesartan in NCT03640312" ] ] [ fhir:reference [ fhir:v "Evidence/367956" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-otherOutcomeMeasure-4-OutcomeAnalysis-15-BetweenGroupAnalysis-OG000-OG001" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Mean Change in Serum Sodium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312" ] ] ) ] ) ] ) ] [ fhir:title [ fhir:v "Mean Change in Blood Urea Nitrogen at 12 weeks" ] ; fhir:focus [ fhir:reference [ fhir:v "EvidenceVariable/367901" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-otherOutcome-5" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Mean Change in Blood Urea Nitrogen at 12 weeks (NCT03640312)" ] ] ; ( fhir:section [ fhir:title [ fhir:v "Outcome Measure Population Description" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasurePopulationDescription" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Measure Reporting Status" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasureReportingStatus" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Measure Time Frame" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasureTimeFrame" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Group List" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeGroupList" ] ] ; ( fhir:section [ fhir:title [ fhir:v "QUARTET LDQT" ] ; fhir:code [ fhir:text [ fhir:v "OG000" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"^^rdf:XMLLiteral ] ; ( fhir:entry [ fhir:display [ fhir:v "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks." ] ] ) ] [ fhir:title [ fhir:v "Candesartan" ] ; fhir:code [ fhir:text [ fhir:v "OG001" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"^^rdf:XMLLiteral ] ; ( fhir:entry [ fhir:display [ fhir:v "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks." ] ] ) ] ) ] [ fhir:title [ fhir:v "Outcome Class List" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeClassList" ] ] ; ( fhir:section [ fhir:title [ fhir:v "Mean Change in Blood Urea Nitrogen at 12 weeks (NCT03640312)" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:reference [ fhir:v "EvidenceVariable/367901" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-otherOutcome-5" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Mean Change in Blood Urea Nitrogen at 12 weeks (NCT03640312)" ] ] ; ( fhir:entry [ fhir:reference [ fhir:v "Evidence/367937" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-otherOutcomeMeasure-5--OG000" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Mean Change in Blood Urea Nitrogen at 12 weeks for QUARTET LDQT in NCT03640312" ] ] [ fhir:reference [ fhir:v "Evidence/367938" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-otherOutcomeMeasure-5--OG001" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Mean Change in Blood Urea Nitrogen at 12 weeks for Candesartan in NCT03640312" ] ] [ fhir:reference [ fhir:v "Evidence/367957" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-otherOutcomeMeasure-5-OutcomeAnalysis-16-BetweenGroupAnalysis-OG000-OG001" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Mean Change in Blood Urea Nitrogen at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312" ] ] ) ] ) ] ) ] [ fhir:title [ fhir:v "Mean Change in Serum Creatinine at 12 weeks" ] ; fhir:focus [ fhir:reference [ fhir:v "EvidenceVariable/367902" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-otherOutcome-6" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Mean Change in Serum Creatinine at 12 weeks (NCT03640312)" ] ] ; ( fhir:section [ fhir:title [ fhir:v "Outcome Measure Population Description" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasurePopulationDescription" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Measure Reporting Status" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasureReportingStatus" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Measure Time Frame" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeMeasureTimeFrame" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>"^^rdf:XMLLiteral ] ] [ fhir:title [ fhir:v "Outcome Group List" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeGroupList" ] ] ; ( fhir:section [ fhir:title [ fhir:v "QUARTET LDQT" ] ; fhir:code [ fhir:text [ fhir:v "OG000" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"^^rdf:XMLLiteral ] ; ( fhir:entry [ fhir:display [ fhir:v "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks." ] ] ) ] [ fhir:title [ fhir:v "Candesartan" ] ; fhir:code [ fhir:text [ fhir:v "OG001" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"^^rdf:XMLLiteral ] ; ( fhir:entry [ fhir:display [ fhir:v "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks." ] ] ) ] ) ] [ fhir:title [ fhir:v "Outcome Class List" ] ; fhir:code [ fhir:text [ fhir:v "OutcomeClassList" ] ] ; ( fhir:section [ fhir:title [ fhir:v "Mean Change in Serum Creatinine at 12 weeks (NCT03640312)" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:reference [ fhir:v "EvidenceVariable/367902" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-otherOutcome-6" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Mean Change in Serum Creatinine at 12 weeks (NCT03640312)" ] ] ; ( fhir:entry [ fhir:reference [ fhir:v "Evidence/367939" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-otherOutcomeMeasure-6--OG000" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Mean Change in Serum Creatinine at 12 weeks for QUARTET LDQT in NCT03640312" ] ] [ fhir:reference [ fhir:v "Evidence/367940" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-otherOutcomeMeasure-6--OG001" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Mean Change in Serum Creatinine at 12 weeks for Candesartan in NCT03640312" ] ] [ fhir:reference [ fhir:v "Evidence/367958" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ; fhir:value [ fhir:v "NCT03640312-otherOutcomeMeasure-6-OutcomeAnalysis-17-BetweenGroupAnalysis-OG000-OG001" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "Mean Change in Serum Creatinine at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312" ] ] ) ] ) ] ) ] ) . #
IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#1.0.0-ballot2 based on FHIR 6.0.0-ballot3. Generated 2025-09-04
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change